News
Shares of Pfizer offer a yield above 7% at recent prices. Pfizer is a pharmaceutical giant that has raised its dividend every ...
The healthcare sector, represented by the Health Care Select Sector SPDR Fund (NYSEARCA:XLV), underperformed the broader ...
2d
Zacks Investment Research on MSNBristol Myers Squibb (BMY) Ascends While Market Falls: Some Facts to NoteBristol Myers Squibb (BMY) closed the most recent trading day at $47.51, moving +2.64% from the previous trading session. The stock's performance was ahead of the S&P 500's daily loss of 0.11%. On the ...
The stock's rise snapped a four-day losing streak.
Cell and gene therapy leaders say the agency’s decision to remove the Risk Evaluation and Mitigation Strategies that had been ...
Bristol Myers Squibb to cut 68 jobs in Lawrenceville as part of a broader restructuring effort aiming to slash $2B in costs ...
BMS is letting go of 68 employees in Lawrenceville, New Jersey. The pharma has now cut over 1,000 employees there since April ...
Bristol-Myers Squibb faces patent losses and growth headwinds despite pipeline gains, debt cuts, and dividends. Read why BMY ...
Princeton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has approved label updates for ...
US FDA approves label updates for Bristol Myers’ CAR T cell therapies, Breyanzi for LBCL & lymphomas and Abecma for multiple myeloma: Princeton, New Jersey Saturday, June 28, 20 ...
The agency will allow BMS to discontinue REMS programs for both therapies and reduce certain patient monitoring requirements.
Label changes remove Risk Evaluation and Mitigation Strategy programs and eases monitoring requirements, supporting broader ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results